尿嘧啶替加氟对Ⅱb～Ⅲ期宫颈癌维持化疗的临床研究

Clinical research of uracil-tegafur for maintenance chemotherapy of stage Ⅱ b～Ⅲ cervical cancer

目的探讨Ⅱb-Ⅲ期宫颈癌同期放化疗后口服尿嘧啶替加氟维持化疗的疗效及不良反应。方法 85例Ⅱb-Ⅲ期宫颈癌患者,随机分为两组,其中维持化疗组40例,该组患者同期放化疗完成后给予口服尿嘧啶替加氟维持化疗至少1年,对照组45例仅随访观察。比较两组患者近期疗效及不良反应。结果维持化疗组无进展生存时间较对照组延长,中位无进展生存时间分别为32个月与27个月,差异有统计学意义（P=0.022〈0.05）。两组骨髓抑制及胃肠道反应发生率比较,差异无统计学意义（P〉0.05）。结论口服尿嘧啶替加氟维持化疗可改善Ⅱb-Ⅲ期宫颈癌生存质量,且未明显增加毒性反应,有望在临床上推广使用。

Objective To investigate the curative effect by oral administration of uracil-tegafur for maintenance chemotherapy of stage Ⅱb～Ⅲ cervical cancer after concurrent chemoradiotherapy. Methods A total of 85 patients with stage Ⅱb～Ⅲ cervical cancer were randomly divided into two groups. Maintenance chemotherapy group with 40 cases received oral administration of uracil-tegafur for at least 1 year after concurrent chemoradiotherapy. Control group with 45 eases received follow-up alone. Short-term effects and adverse reactions of the two groups were compared. Results The maintenance chemotherapy group had longer progression free survival than the control group, and their median progression free survival were respectively 32 months and 27 months. Their difference had statistical significance （P=0.022〈0.05）. There were no statistically significant differences of myelosuppression and incidence of gastrointestinal reactions between the two groups （P〉0.05）. Conclusion Oral administration of uracil-tegafur can improve life quality in stage Ⅱb～Ⅲ cervical cancer, without any increased toxic reactions. This method is worthy of clinical promotion and application.